Featured News

The Celiac Disease Foundation is pleased to announce it will provide patient recruitment and eligibility screening for Anokion’s phase 1b/2 clinical trial for KAN-101.

The PROACTIVE Celiac Study is a phase 2 clinical trial testing the safety and effects of the investigational medication PRV-015.

Anokion SA announced successful completion of its Phase 1 clinical trial evaluating KAN-101 for the treatment of celiac disease, with promising results.

At UEGW, researchers from Takeda, the University of Sheffield, Columbia University, Coeliac UK, and CDF virtually presented a study entitled, Experiences of a gluten-free diet in patients with celiac disease: a multi-national survey.

There are more exciting opportunities than ever before to participate in celiac disease clinical trials. Researchers are making groundbreaking progress in the race for better treatments with promising new drug candidates.

The ACeD Study is looking for volunteers with celiac disease to participate in a phase 1 clinical trial testing the investigational drug KAN-101.

The Foundation is pleased to announce its partnership with Provention Bio to provide clinical trial recruitment for its Phase 2b PROACTIVE Celiac Study for PRV-015 (an anti-interleukin-15 monoclonal antibody).

We put together a list of some of the most common perceived barriers to participating in clinical trials, and how to overcome them.

Parents using multiple kitchen appliances and utensils to prevent their child with celiac disease from being exposed to gluten may be able to eliminate some cumbersome steps. A new, preliminary…

Researchers are collecting blood samples to help develop new diagnostics that may not require gluten ingestion or a biopsy to confirm the diagnosis.